HCPLive Network

Cervical Spine Instabilities Frequently Develop in Patients with Rheumatoid Arthritis

 
MONDAY, Jan. 7 (HealthDay News) -- Nearly half of all patients with rheumatoid arthritis (RA) initially without any cervical spine instabilities will develop some type of instability within about five years, according to research published in the Dec. 15 issue of Spine.

Takashi Yurube, M.D., of the Kobe University Graduate School of Medicine in Japan, and colleagues conducted a prospective, minimum five-year follow-up study of 140 patients with RA and no cervical involvement to assess the incidence and aggravation of cervical spine instabilities.

During approximately six years of follow-up, the researchers found that 43.6 percent of RA patients developed some type of cervical instability. Of these, 32.1 percent developed atlantoaxial subluxation (AAS), 11.4 percent developed vertical subluxation (VS), and 16.4 percent developed subaxial subluxation (SAS). Severe cervical instability was noted in 12.9 percent of all patients (AAS in 3.6 percent, VS in 6.4 percent, and SAS in 5.0 percent), and 4.3 percent developed canal stenosis, defined as space available for the spinal cord of 13 mm or less. Corticosteroid administration, mutilating changes at baseline, and development of non-mutilating into mutilating changes correlated significantly with severe instabilities.

"In conclusion, our prospective follow-up study describes the detailed incidence and predictors of cervical spine instabilities, providing useful information for clinical follow-up in patients with RA," the authors write. "Established mutilating changes and progressive development of non-mutilating into mutilating changes indicate poor prognosis of the cervical spine in patients with RA. Intensive corticosteroid treatment also correlates with the aggravation of cervical spine instabilities in RA; however, its clinical significance needs to be carefully examined."
 

Full Text

Copyright © 2013 HealthDay. All rights reserved.
 

Further Reading
HDL cholesterol may have atheroprotective qualities, according to a report from The New England Journal of Medicine.
Regeneron Pharmaceuticals, Inc. and Sanofi recently announced the US food and Drug Administration (FDA) granted Breakthrough Therapy designation to dupilumab, a fully-human monoclonal antibody, to treat adults suffering from moderate to severe atopic dermatitis (AD)who had an insufficient response to or who were not suitable for topical prescription therapy.
Commoditycare is coming. To distinguish yourself, you will need to innovate and avoid the traps driving your competitors. Patients and payers will be watching you and voting with their wallets.
More Reading